Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387332252> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W4387332252 abstract "<p class=first dir=auto id=d15099657e167>Drug repurposing may be useful in efficiently bringing important new treatments to patients. To help investigators interested in drug repurposing–particularly those in academic or non-profit settings–navigate the regulatory process, we compared available regulatory pathways for repurposed drugs at the European Medicines Agency (EMA), UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA).We focused on 3 repurposing scenarios: a drug never approved by regulators (shelved drug), a marketed product with market exclusivity and/or active patents (new drug), and a drug no longer protected by any exclusivity (generic drug), and created flowcharts to aid academic and non-profit organizations navigate the regulatory landscape. <p dir=auto id=d15099657e169>Repurposing shelved or new drugs must be executed either by or in collaboration with the original intellectual property holder. Shelved drugs can apply for marketing authorization by submitting complete pivotal clinical trials to demonstrate safety and effectiveness. For new drugs, repurposed indications can be added to the product’s label, making sponsors eligible for up to 3 years of market exclusivity under certain conditions. Generics are more accessible for repurposing, and repurposers may not need to collect as extensive preclinical safety data, given that generics have well established safety profiles, though regulators will still require robust clinical evidence of efficacy. Repurposers of generics may collaborate with existing marketing authorization holders to add new indications to drug labels or become marketing authorization holders themselves. <p dir=auto id=d15099657e171>Creating streamlined regulatory pathways for prescription drug repurposing could improve the public health value of this practice. The EU has proposed a new pharmaceutical regulation that aims to facilitate drug repurposing by providing four years of data protection under certain conditions and allowing non-profit entities to submit evidence on new indications to force marketing authorization holders to add the indication to the labeling." @default.
- W4387332252 created "2023-10-05" @default.
- W4387332252 creator A5017459144 @default.
- W4387332252 creator A5021283303 @default.
- W4387332252 creator A5021404933 @default.
- W4387332252 creator A5025170549 @default.
- W4387332252 creator A5027763120 @default.
- W4387332252 creator A5057351979 @default.
- W4387332252 creator A5074257304 @default.
- W4387332252 date "2023-09-29" @default.
- W4387332252 modified "2023-10-14" @default.
- W4387332252 title "Comparing regulatory pathways for drug repurposing in the EU, UK, and US" @default.
- W4387332252 doi "https://doi.org/10.58647/rexpo.23000027.v1" @default.
- W4387332252 hasPublicationYear "2023" @default.
- W4387332252 type Work @default.
- W4387332252 citedByCount "0" @default.
- W4387332252 crossrefType "proceedings-article" @default.
- W4387332252 hasAuthorship W4387332252A5017459144 @default.
- W4387332252 hasAuthorship W4387332252A5021283303 @default.
- W4387332252 hasAuthorship W4387332252A5021404933 @default.
- W4387332252 hasAuthorship W4387332252A5025170549 @default.
- W4387332252 hasAuthorship W4387332252A5027763120 @default.
- W4387332252 hasAuthorship W4387332252A5057351979 @default.
- W4387332252 hasAuthorship W4387332252A5074257304 @default.
- W4387332252 hasBestOaLocation W43873322521 @default.
- W4387332252 hasConcept C103637391 @default.
- W4387332252 hasConcept C108170787 @default.
- W4387332252 hasConcept C108759981 @default.
- W4387332252 hasConcept C108827166 @default.
- W4387332252 hasConcept C111472728 @default.
- W4387332252 hasConcept C127413603 @default.
- W4387332252 hasConcept C138885662 @default.
- W4387332252 hasConcept C142724271 @default.
- W4387332252 hasConcept C144133560 @default.
- W4387332252 hasConcept C162324750 @default.
- W4387332252 hasConcept C175444787 @default.
- W4387332252 hasConcept C17744445 @default.
- W4387332252 hasConcept C181622380 @default.
- W4387332252 hasConcept C199360897 @default.
- W4387332252 hasConcept C2777589142 @default.
- W4387332252 hasConcept C2778917124 @default.
- W4387332252 hasConcept C2779547435 @default.
- W4387332252 hasConcept C2779598192 @default.
- W4387332252 hasConcept C2780035454 @default.
- W4387332252 hasConcept C3019398576 @default.
- W4387332252 hasConcept C3116431 @default.
- W4387332252 hasConcept C38652104 @default.
- W4387332252 hasConcept C41008148 @default.
- W4387332252 hasConcept C519536355 @default.
- W4387332252 hasConcept C548081761 @default.
- W4387332252 hasConcept C60644358 @default.
- W4387332252 hasConcept C71924100 @default.
- W4387332252 hasConcept C86803240 @default.
- W4387332252 hasConcept C98274493 @default.
- W4387332252 hasConceptScore W4387332252C103637391 @default.
- W4387332252 hasConceptScore W4387332252C108170787 @default.
- W4387332252 hasConceptScore W4387332252C108759981 @default.
- W4387332252 hasConceptScore W4387332252C108827166 @default.
- W4387332252 hasConceptScore W4387332252C111472728 @default.
- W4387332252 hasConceptScore W4387332252C127413603 @default.
- W4387332252 hasConceptScore W4387332252C138885662 @default.
- W4387332252 hasConceptScore W4387332252C142724271 @default.
- W4387332252 hasConceptScore W4387332252C144133560 @default.
- W4387332252 hasConceptScore W4387332252C162324750 @default.
- W4387332252 hasConceptScore W4387332252C175444787 @default.
- W4387332252 hasConceptScore W4387332252C17744445 @default.
- W4387332252 hasConceptScore W4387332252C181622380 @default.
- W4387332252 hasConceptScore W4387332252C199360897 @default.
- W4387332252 hasConceptScore W4387332252C2777589142 @default.
- W4387332252 hasConceptScore W4387332252C2778917124 @default.
- W4387332252 hasConceptScore W4387332252C2779547435 @default.
- W4387332252 hasConceptScore W4387332252C2779598192 @default.
- W4387332252 hasConceptScore W4387332252C2780035454 @default.
- W4387332252 hasConceptScore W4387332252C3019398576 @default.
- W4387332252 hasConceptScore W4387332252C3116431 @default.
- W4387332252 hasConceptScore W4387332252C38652104 @default.
- W4387332252 hasConceptScore W4387332252C41008148 @default.
- W4387332252 hasConceptScore W4387332252C519536355 @default.
- W4387332252 hasConceptScore W4387332252C548081761 @default.
- W4387332252 hasConceptScore W4387332252C60644358 @default.
- W4387332252 hasConceptScore W4387332252C71924100 @default.
- W4387332252 hasConceptScore W4387332252C86803240 @default.
- W4387332252 hasConceptScore W4387332252C98274493 @default.
- W4387332252 hasLocation W43873322521 @default.
- W4387332252 hasOpenAccess W4387332252 @default.
- W4387332252 hasPrimaryLocation W43873322521 @default.
- W4387332252 hasRelatedWork W2090884751 @default.
- W4387332252 hasRelatedWork W2339826901 @default.
- W4387332252 hasRelatedWork W2474212275 @default.
- W4387332252 hasRelatedWork W2757705875 @default.
- W4387332252 hasRelatedWork W2897329583 @default.
- W4387332252 hasRelatedWork W2978663398 @default.
- W4387332252 hasRelatedWork W2999793242 @default.
- W4387332252 hasRelatedWork W4225253333 @default.
- W4387332252 hasRelatedWork W4304812360 @default.
- W4387332252 hasRelatedWork W4309044109 @default.
- W4387332252 isParatext "false" @default.
- W4387332252 isRetracted "false" @default.
- W4387332252 workType "article" @default.